No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PHR Phreesia
- 21.940
- -1.200-5.19%
Close Apr 24 16:00 ET
- 21.940
- 0.0000.00%
Post 16:20 ET
1.24BMarket Cap-8741P/E (TTM)
23.130High21.650Low523.44KVolume23.130Open23.140Pre Close11.53MTurnover0.98%Turnover RatioLossP/E (Static)56.39MShares34.97952wk High4.92P/B1.17BFloat Cap12.05052wk Low--Dividend TTM53.50MShs Float81.592Historical High--Div YieldTTM6.40%Amplitude12.050Historical Low22.035Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Phreesia (NYSE:PHR): A Value Play in Healthcare Tech
Express News | NYSE Order Imbalance 65561.0 Shares on Sell Side 65561.0 Shares on Sell Side
Phreesia(PHR.US) Officer Sells US$63,928.07 in Common Stock
$Phreesia(PHR.US)$ Officer Gunzburg Janet sold 2,768 shares of common stock on Apr 10, 2024 at an average price of $23.0954 for a total value of $63,928.07.Source: Announcement What is statement of ch
Health Check: How Prudently Does Phreesia (NYSE:PHR) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it might
R1 RCM, Health Catalyst Downgraded as KeyBanc Reviews Health-tech Space
Form 144 | Phreesia(PHR.US) Officer Proposes to Sell 105.89K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 9, $Phreesia(PHR.US)$ Officer ALLISON HOFFMAN intends to sell 4,626 shares of its common stock on Apr 9, with a total market value of approximately $105.89K. Source: Ann
Comments
Investor confidence, reflected in a high P/S ratio and increasing share prices despite fluctuations, suggests anticipated persistent growth in Phreesia. Caution advised over sole reliance on price-to-sales ratios for investment decisions.
Phreesia, Inc.'s (NYSE:PHR) P/S Is Still On The Mark Following 43% Share Price Bounce
ColumnsToday's pre-market stock movers: TSLA, CHGG, OKTA, TPTX and more
Gainers:
• $Okta(OKTA.US$ +15.8% (In reaction to earnings)
• $StoneCo(STNE.US$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics(TPTX.US$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals(AMLX.US$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
• $Okta(OKTA.US$ +15.8% (In reaction to earnings)
• $StoneCo(STNE.US$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics(TPTX.US$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals(AMLX.US$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
25
2
ColumnsTop upgrades and downgrades on 4/14
Upgrades
• $CDW Corp(CDW.US$: Stifel Upgrades to Buy from Hold - PT $210 (from $200)
• $Corteva(CTVA.US$ : Loop Capital Upgrades to Buy from Hold - PT $69
• $CoreCivic, Inc.(CXW.US$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $10.85)
• $Delta Air Lines(DAL.US$ : Barclays Upgrades to Overweight from Equalweight - PT $60 (from $42)
• $H.B. Fuller(FUL.US$ : Baird Upgrades to Outperform from Neutral - PT $85
• $Huntington Ingalls Industries(HII.US$ : Cowen U...
• $CDW Corp(CDW.US$: Stifel Upgrades to Buy from Hold - PT $210 (from $200)
• $Corteva(CTVA.US$ : Loop Capital Upgrades to Buy from Hold - PT $69
• $CoreCivic, Inc.(CXW.US$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $10.85)
• $Delta Air Lines(DAL.US$ : Barclays Upgrades to Overweight from Equalweight - PT $60 (from $42)
• $H.B. Fuller(FUL.US$ : Baird Upgrades to Outperform from Neutral - PT $85
• $Huntington Ingalls Industries(HII.US$ : Cowen U...
19
ColumnsToday's pre-market stock movers: CLVS, PATH, DARE and more
Gainers:
• $Clovis Oncology(CLVS.US$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience(DARE.US$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology(KULR.US$ +9.5% (secured a battery sa...
• $Clovis Oncology(CLVS.US$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience(DARE.US$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology(KULR.US$ +9.5% (secured a battery sa...
14
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg